The Role of Bisphosphonates in Preventing Fragility Fractures: A 10-Year Follow-Up Study
DOI:
https://doi.org/10.63682/jns.v14i6.4086Keywords:
Bisphosphonates, Fragility Fractures, Osteoporosis, Bone Mineral Density, Long-Term EfficacyAbstract
Bisphosphonates serve as a pharmaceutical treatment to stop fractures among people who have osteoporosis which shows itself through reduced bone mineral density and elevated susceptibility to bone-breaking fractures. The purpose of this research is to determine how well bisphosphonates prevent fragility fractures during a 10-year observation period. The analysis included data about fracture occurrences and BMD changes and bisphosphonate safety measurements with special attention given to rare side effects such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures. A research sample included people who were 50 years old or older with osteoporosis or those who had a high risk of bone fractures. The bisphosphonate treatment group achieved statistically lower rates of both vertebral and hip fractures compared to the control group. The treatment led to higher bone mineral density levels at the hip region and at the lumbar spine. The research demonstrated that bisphosphonate therapy extends risks through the development of osteonecrosis of the jaw (ONJ) and atypical femoral fractures. The research highlights the necessity for individualized therapy plans and additional studies about the best duration of treatment together with drug breaks and long-term treatment consequences.
Downloads
Metrics
References
Adachi, J. D., Hanley, D. A., & Felsenberg, D. (2013). Long-term bisphosphonate therapy: Drug holidays and the risk of atypical femoral fractures. Current Osteoporosis Reports, 11(3), 99-106.
Cumming SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group. In Classic Papers in Rheumatology (pp. 316-318). CRC Press.
Cummings, S. R., Black, D. M., Thompson, D. E., Applegate, W. B., Barrett-Connor, E., Musliner, T. A., ... & Fracture Intervention Trial Research Group. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama, 280(24), 2077-2082.
Deardorff, W. J., Cenzer, I., Nguyen, B., & Lee, S. J. (2022). Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Internal Medicine, 182(1), 33-41.
Dieppe, P., Wollheim, F. A., & Schumacher, H. R. (2001). Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fracture: Black DM,
Durie, B. G., Katz, M., & Crowley, J. (2005). Osteonecrosis of the jaw and bisphosphonates. N Engl j Med, 353(1), 99-102.
Goldhahn, J., Suhm, N., Goldhahn, S., Blauth, M., & Hanson, B. (2008). Influence of osteoporosis on fracture fixation-a systematic literature review. Osteoporosis international, 19, 761-772.
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., & Reginster, J. Y. (2013). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis international, 24(1), 23-57.
Kannus, P., Parkkari, J., Sievänen, H., Heinonen, A., Vuori, I., & Järvinen, M. (1996). Epidemiology of hip fractures. Bone, 18(1), S57-S63.
Rodan, G. A., & Fleisch, H. A. (1996). Bisphosphonates: mechanisms of action. The Journal of clinical investigation, 97(12), 2692-2696.
Sanderson, J., Martyn-St James, M., Stevens, J., Goka, E., Wong, R., Campbell, F., ... & Davis, S. (2016). Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis. Bone, 89, 52-58.
Tei, R. M., Ramlau-Hansen, C. H., Plana-Ripoll, O., Brink, O., & Langdahl, B. L. (2019). OFELIA: prevalence of osteoporosis in fragility fracture patients. Calcified tissue international, 104, 102-114.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
